Quantification of modified amyloid β peptides in Alzheimer disease and Down syndrome brains

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 11, 1998, Pages 1089-1095

  Hosoda, Ritsuko ^a,b   Saido, Takaomi C ^c   Otvos Jr , Laszlo ^d   Arai, Takao ^b   Mann, David M A ^e   Lee, Virginia M Y ^f   Trojanowski, John Q ^f   Iwatsubo, Takeshi ^a,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d WISTAR INSTITUTE   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Alzheimer disease; Amyloid II peptide; Down Syndrome; Enzyme linked immunosorbent assay; Modification; Senile plaque

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL LOBE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENILE PLAQUE;

EID: 0031729335     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199811000-00012     Document Type: Article

References (31)

1. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98
2. Selkoe DJ. Cell biology of the amyloid β-protein presursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994;10: 373-403
3. Citron M, Oltersdolf T, Haass C, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 1992;360:672-74
4. Cai X-D, Golde TE, Younkin SG. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 1993;259:514-16
5. Suzuki N, Cheung TT, Cai X-D, et al. An increased percentage of long amyloid β-protein is secreted by familial amyloid β-protein precursor (βAPP717) mutants. Science 1994;264:1336-40
6. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005-13
7. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383: 710-13
8. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 1997;3: 67-72
9. Tomita T, Maruyama K, Saido TC, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997;94:2025-30
10. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-83
11. Miller DL, Papayannopoulos IA, Styles J, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993;301:41-52
12. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53
13. Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol 1995;37:294-99
14. Fukumoto H, Asami-Odaka A, Suzuki N, Shimada H, Ihara Y, Iwatsubo T. Amyloid β protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of Aβ42(43) and association of Aβ40 with cored plaques. Am J Pathol 1996;148:259-65
15. Tamaoka A, Odaka A, Ishibashi Y, et al. APP717 missense mutation affects the ratio of amyloid β protein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease. J Biol Chem 1994;269:32721-24
16. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 1992;267:17082-86
17. Saido TC, Iwastubo T, Mann DMA, Shimada H, Ihara Y. Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995;14: 457-66
18. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino-and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neurosci Lett 1996;215:173-76
19. Iwatsubo T, Saido TC, Mann DMA, Lee VM-Y, Trojanowski JQ. Full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am J Pathol. 1996;149:1823-30
20. Tekirian TL, Saido TC, Markesbery WR, et al. N-terminal heterogeneity of parenchymal and cerebrovascular Aβ deposits. J Neuropathol Exp Neurol 1998;57:76-94
21. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-97
22. Szendrei GI, Prammer KV, Vasko M, Lee VM-Y, Otvos LJr. The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments. Int J Peptide Res 1996;47:289-96
23. Szendrei GI, Fabian H, Mantsch HH, et al. Aspartate-bond isomerization affects the major conformations of synthetic peptides. Eur J Biochem 1994;226:917-24
24. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble β 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 1994;145:452-60
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44
26. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105
27. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J Biol Chem 1995;270:23895-98
28. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996;2:93-95
29. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid β-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 1997;409: 411-16
30. Kim E, Lowenson JD, MacLaren DC, Clarke S, Young SG. Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci USA 1997;94:6132-37
31. Yamamoto A, Takagi H, Kitamura D, et al. Deficiency in protein L-isoaspartyl methyltransferase results in a fatal progressive epilepsy. J Neurosci 1998;18:2063-74